1. Pink Sheet

First Three Medicine Regulators Gain ‘WHO-Listed Authority’ Status

 
• By Ian Schofield

The WLA nominations have kicked off a voluntary evaluation process intended to identify “reference” regulatory authorities and improve international reliance and cooperation.

the happiness of the person reaching the goal after a determined and patient struggle
Three national regulators have made it to the WHO's top ranking • Source: Shutterstock

The World Health Organization has announced that the regulatory agencies of Singapore, South Korea and Switzerland have become the first three “WHO-Listed Authorities” under a new framework intended to promote the harmonization of regulatory standards and practices at global level.

The WHO said the decisions were a “significant milestone” for the countries concerned and represented “global recognition that these three regulatory authorities meet WHO and other

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England

 
• By Francesca Bruce

BioMarin’s ultra-rare disease drug Brineura has breached cost-effectiveness thresholds for highly specialized treatments in England and looks set to be denied routine funding on the National Health Service.

Inclusive By Design: UK Pilots Diversity Plans For Drug & Device Trials

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

UK’s International Recognition Procedure: EU Dossier Faster Than US Or Canada

 
• By Eliza Slawther

Companies that use the European Medicines Agency as a reference regulator for the UK’s International Recognition Procedure can expect a faster approval than those that use other national regulators, such as those in the US and Canada, an MHRA spokesperson has said.